The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy (Arm A) and valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy (Arm B)
Source: View publication →
The SANAD trial established lamotrigine as a preferred first-line treatment for partial-onset epilepsy due to better tolerability over carbamazepine, while confirming valproate as the most effective first-line option for generalized and unclassifiable epilepsies.
Key Findings
Study Design
Study Limitations
Clinical Significance
The SANAD study provided definitive, long-term comparative evidence that reshaped clinical practice globally. For focal (partial) epilepsy, it established lamotrigine as the new first-line therapy of choice due to its superior tolerability and non-inferior efficacy compared to carbamazepine. For generalized and unclassifiable epilepsies, it reinforced valproate as the most effective agent, significantly outperforming newer drugs like topiramate and lamotrigine. However, the study highlighted the ongoing clinical challenge of balancing valproate's superior efficacy against its known teratogenicity in women of childbearing potential.
Historical Context
Before the SANAD trial, evidence for antiepileptic drug (AED) efficacy was primarily derived from short-term, placebo-controlled, regulatory add-on trials. There was a critical void of long-term, head-to-head comparative effectiveness data between older standard AEDs (carbamazepine, valproate) and the newer generation of drugs (lamotrigine, gabapentin, topiramate, oxcarbazepine). Commissioned by the UK's National Institute for Health Research (NIHR), the SANAD trial was a landmark pragmatic study that shifted the clinical paradigm from solely measuring 'seizure freedom' to emphasizing 'time to treatment failure'—a composite metric reflecting real-world efficacy, tolerability, and drug retention.
Guided Discussion
High-yield insights from every perspective
How do the mechanisms of action differ between carbamazepine, which the SANAD study evaluated for partial seizures, and valproate, which was evaluated for broad-spectrum coverage in generalized epilepsies?
Key Response
Carbamazepine primarily blocks voltage-gated sodium channels, making it effective for focal (partial) onset seizures. Valproate has multiple mechanisms including sodium channel blockade, T-type calcium channel modulation, and increasing GABA levels, providing the broad-spectrum efficacy needed for generalized and unclassifiable epilepsies.
The SANAD trial established valproate as the most effective first-line agent for generalized epilepsy. How does this finding complicate the management of a 22-year-old female patient newly diagnosed with generalized epilepsy, and what alternatives should be considered?
Key Response
Valproate is highly teratogenic, causing neural tube defects and cognitive impairment in offspring. For women of childbearing potential, balancing the superior efficacy of valproate shown in SANAD against its teratogenic risks requires considering alternatives like lamotrigine or levetiracetam, despite them potentially having lower efficacy for certain generalized seizure types.
In SANAD Arm A, lamotrigine was preferred over carbamazepine due to a longer time to treatment failure. However, how did the two drugs compare regarding the secondary outcome of time to 12-month remission, and how does this nuance affect drug selection?
Key Response
Carbamazepine actually showed a slight trend toward better efficacy for absolute seizure control (time to 12-month remission) compared to lamotrigine, but lamotrigine won the primary outcome of 'time to treatment failure' due to significantly better tolerability. A fellow must weigh whether to push through initial carbamazepine side effects for a potentially higher chance of absolute remission in highly motivated patients.
SANAD was an unblinded, pragmatic effectiveness trial rather than a double-blind efficacy trial. How does this design choice more accurately reflect real-world clinical practice, and how should it influence patient counseling regarding antiepileptic drug initiation?
Key Response
Pragmatic trials measure 'effectiveness' (real-world performance heavily influenced by tolerability and adherence) rather than pure pharmacological 'efficacy'. This teaches us that counseling on side-effect management is as critical to long-term seizure freedom as the molecular efficacy of the drug, as most treatment failures are due to adverse effects rather than lack of efficacy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
How might the unblinded nature of the SANAD trial have introduced differential ascertainment bias into the primary outcome of 'time to treatment failure', and what statistical sensitivity analyses could be employed to estimate the magnitude of this bias?
Key Response
Lack of blinding can influence both the patient's and physician's threshold to withdraw a drug due to perceived side effects, directly impacting the 'time to treatment failure' survival curve. Analyzing objective versus subjective reasons for withdrawal and using competing risk models would help disentangle true pharmacological failure from bias-driven withdrawal.
Arm B of the SANAD trial included a significant proportion of patients with 'unclassifiable' epilepsy. From an editorial standpoint, how does pooling this heterogeneous cohort with generalized epilepsy threaten the internal validity of the conclusion that valproate is superior?
Key Response
Unclassifiable epilepsy might include undiagnosed partial epilepsies where valproate performs differently. Pooling these dilutes the true efficacy signal for purely generalized epilepsies. A rigorous reviewer would demand stratified analyses to ensure the valproate superiority was not driven by misclassified focal cases, ensuring robust internal validity.
Given the SANAD trial's pragmatic, unblinded design, how should guideline committees grade the quality of evidence when recommending lamotrigine as a first-line agent for partial epilepsy, and how does this highlight discrepancies between NICE and AAN/AES guideline methodologies?
Key Response
AAN/AES guidelines typically require Class I evidence (demanding double-blinding) for a Level A recommendation, whereas NICE guidelines heavily favor pragmatic trials reflecting real-world effectiveness. Because SANAD was unblinded, it might be downgraded in rigorous efficacy-based grading systems, highlighting the tension between evaluating real-world utility versus strict pharmacological efficacy in guideline development.
Clinical Landscape
Noteworthy Related Trials
VA Cooperative Study 118
Tested
Carbamazepine, phenobarbital, primidone, or phenytoin
Population
Adults with partial and secondarily generalized seizures
Comparator
Active head-to-head comparison
Endpoint
Retention in the trial (composite of efficacy and toxicity)
MESS Trial
Tested
Immediate antiepileptic drug treatment
Population
Patients with a single unprovoked seizure or early epilepsy
Comparator
Deferred treatment
Endpoint
Time to first seizure and time to 2-year remission
SANAD II Trial
Tested
Levetiracetam or zonisamide
Population
Patients with newly diagnosed focal epilepsy
Comparator
Lamotrigine
Endpoint
Time to 12-month remission
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis